Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood (2021) 138 (25): 2727–2730.

https://doi.org/10.1182/blood.2021011883

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System

Andrea Visentin, MDPhD, Gian Matteo Rigolin, Francesca Romana Mauro, MD PhD, Annalisa Martines, PhD, Federica Frezzato, PhD, Silvia Imbergamo, MD, Stefano Pravato, MD, Leila Romano Gargarella, MD, Maria Antonella Bardi, Mauro Nanni, PhD, Francesco Piazza, Monica Facco, MS, Robin Foà, MD, Gianpietro Semenzato, MD, Laura Bonaldi, MD, Antonio Cuneo, MD, Livio Trentin, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136605

Published: 2020

Journal Articles

The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia

Blood (2018) 132 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2018-99-114721

Published: 2018

Journal Articles

Management of Chronic Myeloid Leukemia in Children and Adolescents According to Local Guidelines.the Italian Experience

Blood (2016) 128 (22): 3083.

https://doi.org/10.1182/blood.V128.22.3083.3083

Published: 2016

Journal Articles

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Blood (2015) 126 (23): 2946.

https://doi.org/10.1182/blood.V126.23.2946.2946

Published: 2015

Journal Articles

Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience

Blood (2015) 126 (23): 2788.

https://doi.org/10.1182/blood.V126.23.2788.2788

Published: 2015

Journal Articles

Response to High Dose Imatinib and Long-Term Outcome in Children and Adolescents with Previously Untreated Chronic Myeloid Leukemia in Chronic Phase. the Italian Experience

Blood (2014) 124 (21): 1812.

https://doi.org/10.1182/blood.V124.21.1812.1812

Published: 2014

Journal Articles

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

Roberto Latagliata, MD, Ida Carmosino, Federico Vozella, Paola Volpicelli, MD, Giuseppina Loglisci, Michelina Santopietro, Adriano Salaroli, MD, Angela Romano, Chiara Montagna, Amanda Roberto, Alessandra Serrao, Daniela Diverio, PhD, Mauro Nanni, PhD, Marco Mancini, Agostino Tafuri, Massimo Breccia, Giuliana Alimena, MD

Blood (2013) 122 (21): 4002.

https://doi.org/10.1182/blood.V122.21.4002.4002

Published: 2013

Journal Articles

High Dose Imatinib Is Effective In Children and Adolescents With Chronic Myelogenous Leukemia In Chronic Phase. The Italian Experience

Blood (2013) 122 (21): 1490.

https://doi.org/10.1182/blood.V122.21.1490.1490

Published: 2013

Journal Articles

Can Children and Adolescents With Chronic Myelogenous Leukemia Be Cured Without Stem Cell Transplant? A Single Center Experience

Fiorina Giona, Benedetta Siniscalchi, Maria Luisa Moleti, Massimiliano Rea, Deborah Marzella, Mauro Nanni, Enrico Gottardi, Anna Paola Iori, Daniela Diverio, Anna Maria Testi, Giuseppe Saglio, MD, Robin Foa'

Blood (2013) 122 (21): 4033.

https://doi.org/10.1182/blood.V122.21.4033.4033

Published: 2013

Journal Articles

Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression

Giuseppe Zardo, Alberto Ciolfi, Laura Vian, Linda M. Starnes, Monia Billi, Serena Racanicchi, Carmen Maresca, Francesco Fazi, Lorena Travaglini, Nelida Noguera, Marco Mancini, Mauro Nanni, Giuseppe Cimino, Francesco Lo-Coco, Francesco Grignani, Clara Nervi

Blood (2012) 119 (17): 4034–4046.

https://doi.org/10.1182/blood-2011-08-371344

Published: 2012

Includes: Supplemental data

Journal Articles

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

Fiorina Giona, Luciana Teofili, Maria Luisa Moleti, Maurizio Martini, Giovanna Palumbo, Angela Amendola, Maria Gabriella Mazzucconi, Anna Maria Testi, Patrizia Pignoloni, Sonia Maria Orlando, Sara Capodimonti, Mauro Nanni, Giuseppe Leone, Luigi Maria Larocca, Robin Foà

Blood (2012) 119 (10): 2219–2227.

https://doi.org/10.1182/blood-2011-08-371328

Published: 2012

Includes: Supplemental data

Journal Articles

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

Roberto Latagliata, Massimo Breccia, Ida Carmosino, Federico Vozella, Paola Volpicelli, Antonietta Ferretti, Giuseppina Loglisci, MD, Michelina Santopietro, Vincenzo Federico, Rosa De Cuia, Daniela Diverio, Mauro Nanni, PhD, Marco Mancini, Giuliana Alimena

Blood (2011) 118 (21): 3783.

https://doi.org/10.1182/blood.V118.21.3783.3783

Published: 2011

Journal Articles

13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia

Blood (2010) 116 (21): 3578.

https://doi.org/10.1182/blood.V116.21.3578.3578

Published: 2010

Journal Articles

Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features

Massimo Breccia, PhD, Paola Finsinger, Roberto Latagliata, MD, Laura Cannella, PhD, Giuseppina Loglisci, PhD, Mauro Nanni, PhD, Michelina Santopietro, PhD, Adriano Salaroli, PhD, Agostino Tafuri, Giuliana Alimena, PhD

Blood (2010) 116 (21): 4976.

https://doi.org/10.1182/blood.V116.21.4976.4976

Published: 2010

Journal Articles

Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study

Francesca Romana Mauro, MD, Daniele Armiento, MD, Sonia Orlando, BS, Ilaria Del Giudice, MD, Maria Stefania De Propriis, PhD, Mauro Nanni, PhD, Marilisa Marinelli, PhD, Molica Matteo, Paola Fazi, MD, Francesca Paoloni, BS, Graziosi Antonietta, Laura Collada, Anna Guarini, PhD, Robin Foà, MD

Blood (2010) 116 (21): 1377.

https://doi.org/10.1182/blood.V116.21.1377.1377

Published: 2010

Journal Articles

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Blood (2010) 116 (21): 2471.

https://doi.org/10.1182/blood.V116.21.2471.2471

Published: 2010

Journal Articles

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

Blood (2009) 114 (24): 4939–4943.

https://doi.org/10.1182/blood-2009-07-229864

Published: 2009

Includes: Supplemental data

NARROW

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System

The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia

Management of Chronic Myeloid Leukemia in Children and Adolescents According to Local Guidelines.the Italian Experience

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience

Response to High Dose Imatinib and Long-Term Outcome in Children and Adolescents with Previously Untreated Chronic Myeloid Leukemia in Chronic Phase. the Italian Experience

Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a “Real-life” Patient Population With Chronic Myelogenous Leukemia?

High Dose Imatinib Is Effective In Children and Adolescents With Chronic Myelogenous Leukemia In Chronic Phase. The Italian Experience

Can Children and Adolescents With Chronic Myelogenous Leukemia Be Cured Without Stem Cell Transplant? A Single Center Experience

Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia,

13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia

Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features

Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only